L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach.
Rascol
O
O
Clinical Pharmacological Laboratory, INSERM U 455 and Clinical Investigation Centre, University Hospital, Toulouse, France.
D000978:Antiparkinson Agents / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004409:Dyskinesia, Drug-Induced / Q000175:diagnosis / Q000209:etiology*; D018698:Glutamic Acid / Q000378:metabolism; D006801:Humans; D007980:Levodopa / Q000009:adverse effects*; D009294:Narcotics / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism; D010300:Parkinson Disease / Q000188:drug therapy*; D011954:Receptors, Dopamine / Q000187:drug effects; D012701:Serotonin / Q000378:metabolism
D000978:Antiparkinson Agents; D009294:Narcotics; D011954:Receptors, Dopamine; D012701:Serotonin; D018698:Glutamic Acid; D007980:Levodopa; D009638:Norepinephrine